On January 29th, 2024, Oxford Biomedica plc acquired Oxford Biomedica France. The acquisition of Oxford Biomedica France, a pure-play European CDMO, strengthens Oxford Biomedica’s position as a world-leading cell and gene therapy CDMO. This strategic move broadens the Company’s international development, manufacturing and testing presence, services, and capacity by establishing a strong footprint within the EU with facilities in Lyon and Strasbourg, France.
In addition, the acquisition increases Oxford Biomedica’s capacity in process and analytical development and early- stage manufacturing across Adenovirus, Lentiviral vectors, AAVs, and with this acquisition, MVA and Vaccinia. For more information on the acquisition, see the press release links below.
Oxford, UK – 29 January 2024: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that, following the announcements on 20 September and 4 December 2023, it has today completed the acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA (“Institut Mérieux”).
Oxford, UK – 4 December 2023: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that it has entered into a sale and purchase agreement (the “Agreement”)…
Oxford, UK – 20 September 2023: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, and Institut Mérieux SA (“Institut Mérieux”) today announce that they have entered into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe SAS…